By API User
EBR Systems, Inc. (ASX: EBR) (“EBR Systems”, “the Company”), developer of the world’s only left ventricular wireless cardiac pacing device for heart failure, is pleased to report the recent publication of two studies reporting on new, unapproved, clinical applications of the WiSE® System in patients suffering from heart failure. Application 1: WiSE® used to deliver … Continued
By API User
Highlights • Less than two months after FDA clearance, Stanford University becomes the first U.S. Academic Medical Centre (AMC) to adopt CT:VQ™ under a commercial contract • 4DMedical and AstraZeneca expand the Lung Health Screening Program in Brazil to five additional hospitals, covering 38,000 CT scans annually Melbourne, Australia, 22 October 2025: 4DMedical Limited (ASX: 4DX, … Continued
By API User
22 October 2025 – Sydney, Australia | BlinkLab Limited (ASX:BB1), an ASX-listed digital healthcare company developing AI-powered diagnostic tools, today announced the successful completion and unblinding of its U.S. Pilot Study evaluating the performance of its smartphone-based autism diagnostic test, BlinkLab Dx 1. The pilot results demonstrate strong diagnostic accuracy, while a recent meeting with … Continued
By API User
21 October 2025 – Melbourne, Australia | Nexsen Limited (ASX:NXN), a nano-biotechnology company pioneering next-generation technology in point-of-care diagnostics, has announced the commencement of a pivotal clinical trial for its GBS Rapid Sensor, which is going to be marketed under the proprietary name StrepSure®. The clinical trial marks a significant step in the validation of … Continued
By API User
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC) No dose-limiting toxicities and no treatment-related serious adverse events observed Xerostomia predominantly Grade 1 80% PSA50 response at doses ≥ 160 MBq 100% objective response rate (ORR) in … Continued
By API User
Enterprise platform, queried through natural language, to help pharma, biotech, and investors make better decisions. High-quality biological patient data, enriched and integrated for use by AI agents. PARIS, FRANCE, GB / ACCESS Newswire / October 16, 2025 / Owkin today announces the launch of K Pro, its co-pilot bringing advanced agentic AI to biomedical research … Continued
By API User
Kay was instrumental in driving the successful development and commercialization ofXofigo®, the first and only approved alpha therapy to date SYDNEY, Australia – October 16, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Andrew Kay as Director and Chair-elect of its Board of Directors, … Continued
By API User
Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) is pleased to announce the first patient treatment in Germany using the OncoSil™ device. The successful treatment was performed on 15 October 2025 at Universitätsklinikum Augsburg, a leading university hospital renowned for its excellence in oncology. This important milestone marks the commencement of OncoSil’s commercial activities in Germany, the … Continued
By API User
14 October 2025 – Sydney, Australia | Nexsen Limited (ASX:NXN), an Australian nano-biotechnology company developing a next-generation point-of-care diagnostic platform, has today commenced trading on the Australian Securities Exchange (ASX) following a successful $8 million capital raising as part of its Initial Public Offering (IPO). The capital raised in the IPO will accelerate the development … Continued
By API User
Series A led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, a biotechnology company harnessing neural circuits to restore immune homeostasis in disease, launched today with a $101 million Series A financing led by … Continued
